Nemysis Team

The Leadership Team and Advisory Boards bring a depth and breadth of knowledge and skills

Within Nemysis we run a lean Leadership Team with diverse and complementary skill sets with extensive expertise and successful track records in specialty pharma.

We have strong scientific, R&D, medical, pharmaceutical, and commercial know-how to bring products to market. We have a clear aspiration and commitment to utilise cutting edge science and technology to address unmet clinical needs. Within the team, we have solid experience of starting up, developing, growing, and divesting specialty pharma companies.

The Leadership Team is supported by our highly respected scientific advisory board who provide specialist support.  It is composed of a strong network of scientists and clinicians from academic and health institutions across the EU, and who are renowned experts in their field.

Directors & Executive Management Team

Danilo Casadei Massari

Danilo Casadei Massari

Chairman & CEO

Founder and CEO, Danilo has extensive experience as a senior pharmaceutical executive and as an entrepreneur. He was President and CEO of Fidia Pharmaceuticals, USA, and Director of International Corporate Development with Fidia Farmaceutici S.p.A. He also served as VP, Corporate Development at Madaus AG and held several senior management positions in several Pharma Companies. As a serial entrepreneur he has founded several pharmaceutical companies, including, CM&D Pharma Limited, a company focused on prescription Medical Foods, which was acquired by Nestle Health Science in 2011.

Maria Cristina Comelli

Maria Cristina Comelli

Director R&D

A passionate researcher into the relationship between epigenetics and nutrition. Her focus is the role that specific nutrients could exert in primary, and particularly in secondary, prevention of chronic diseases as functional adjuncts to medicinal products. Cristina has held senior R&D management positions in a number of European companies, is an inventor on numerous patents and often consults on regulatory affairs. She served as director in CM&D Pharma, acquired by Nestle Health Science. Cristina is a Member of the Board in ExPharma Limited, a UK based R&D Company.

Marco Cartolari

Marco Cartolari

Chief Operating Officer

Marco Cartolari is an entrepreneur with over 25 years of managerial and entrepreneurial experience in a range of industries, including healthcare and financial services. Ex-CEO of a pharmaceutical company in Europe, Marco currently advises, invests in and serves on the board of a variety of start-up businesses. Marco has an MBA in Marketing and Finance from Columbia University and a BA (Laurea) in Business Administration from Bocconi University, Milan.

Estrella Bengio

Estrella Bengio

Head, Regulatory Affairs

Estrella is a senior Regulatory Affairs expert with more than 30 years of experience and expertise in Healthcare and Pharmaceuticals. She has served as Regulatory Affairs Director at Abbott Nutrition covering a broad range of countries. She was a member of the Board of Specialized Nutrition Europe, SNE, covering Food for Special Medical Purposes and Public Affairs and has also covered a leading role in the regulatory area in Medical Nutrition International Industry, MNI. Estrella has a Master´s in Pharmacy and Nutrition from the Complutense University of Madrid.

Non-Executive Directors

Paul Ranson

Paul Ranson

Non-Executive Director

A highly experienced lawyer with many years’ experience of the life sciences industry. A Barrister for 2 years, Legal Adviser and subsequently Manager, Legal Affairs at Smith Kline UK for 4 years. Director, Legal Affairs at Merck Sharp & Dohme UK for 5 years. Associate and subsequently Head of Life Sciences at Simmons & Simmons (UK law firm) for 11 years. Partner and Head of International Life Sciences at Fasken Martineau (Anglo-Canadian law firm) for 12 years. Partner, Life Sciences, Pinsent Masons (solicitors) for 2 years. In private practice core clients over the years have included big pharma/medtech (e.g. Novartis, AZ, Merck US and Merck Serono, Lilly, Novo, Boehringer, UCB, Becton Dickinson, Smith & Nephew, Teva, Allergan.

R.V. Venkatesh

R.V. Venkatesh

Non-Executive Director

A Chemist with over 30 years’ experience in Healthcare Industry, in Pharmaceuticals and Nutraceuticals. He is one of the founders and Managing Director of Gencor group worldwide. He has extensive experience in International Business in the Pharmaceutical and Nutraceutical sectors worldwide, having conducted business in over 70 countries. He has extensive experience in R&D Management, scientific reviews, product development, clinical trials, branding, strategic partnerships and has a track record of successful branded product launches worldwide in the nutraceutical segment.

Guru Ramanathan

Guru Ramanathan

Non-Executive Director

Guru is a Senior Executive specialising in Global Healthcare innovation management and commercialisation. He served as Chief Innovation Officer at General Nutrition Corporation and, before that, he was Sr. Director of Scientific Affairs at Royal Numico (now Nutricia-Danone). Guru has MBA in general management with special emphasis on global business practices, and a Ph.D in healthcare innovation management, focused upon customer centric R&D, strategic business planning and pre & post marketing activities. A clinician by discipline, Guru specialised in cranio-facial growth & development, with 35 years of clinical and research experience both within and outside the US.

Howard Lossing

Howard Lossing

Non-Executive Director

Howard is CEO of Ajinomoto Cambrooke, Inc., a fast-growing leader in Medical Nutrition for people with chronic health conditions. He previously held numerous medical nutrition leadership positions with Nutricia (a subsidiary of Danone) guiding business strategy, development and acquisitions during his tenure based in the US, Canada and the United Kingdom. Howard was previously an executive in two successful start-up technology firms and with Procter & Gamble (P&G) in several brand management positions in P&G’s Health Care and Paper divisions.

Antonio Maggi

Antonio Maggi

Non-Executive Director

Antonio Maggi is a manager with over 30 years of managerial and entrepreneurial experience in a range of industries, including healthcare and petroleum. Ex-CEO and Managing Director of a pharmaceutical company in Italy, Antonio has also gained broad experience in pharmaceutical marketing and sales networks management. Currently he works with the board of a variety of start-up businesses. Antonio has a Master’s Degree in Economics from Politecnico delle Marche University of Ancona.

Alia Minhas

Alia Minhas

Non-Executive Director

Alia is a Director and Co-founder of The Life Sciences Division, a UK based, FCA regulated Investment bank serving the global life sciences industry. She has previously established private equity and offshore funds and co-created a number of life sciences private equity backed businesses. Executing on fundraising, mergers, acquisitions and divestments. Alia worked as a buy side equity analyst and Associate Director in the biotech sector at Mulier Capital, an Investment bank and Investment management firm that specialised in gene therapies. Prior to this, Alia’s formative banking career was at Lloyds Banking Group and Scottish Widows Investment Partnership.

Scientific Advisory Board

Prof. Jonathan Powell

Prof. Jonathan Powell

Head of Bio-Mineral Research at University of Cambridge

Professor Jonathan Powell is Head of Bio-Mineral Research at Cambridge University, where he and his team work with trace elements and mineral structures, especially nanoparticles, trying to identify their benefit to health as part of normal physiology. Prior to his current position, he was Head of Bio-mineral Research at the MRC’s Human Nutrition Research (‘‘HNR’’) Elsie Widdowson Laboratory in Cambridge. Within HNR, his work focused on the absorption of iron and diagnosis and treatment of iron deficiency; the role of minerals in inflammatory and anti-inflammatory processes of the gastrointestinal tract and the development of novel mineral-based therapeutics. Prof Powell and his team were the inventors of the patented technology behind IHAT which Nemysis Ltd acquired the licence from the MRC in late 2017.

Dr Nuno Faria

Dr Nuno Faria

Chief Scientific Officer at NoBACZ Healthcare Ltd

Nuno is currently Chief Scientific Officer at NoBACZ Healthcare Ltd. He worked with Professor Powel at the Bio-Mineral Research at the MRC’s Human Nutrition Research (‘‘HNR’’) Elsie Widdowson Laboratory in Cambridge, where his work focused on the absorption of iron and diagnosis and treatment of iron deficiency; the role of minerals, in inflammatory and anti-inflammatory processes of the gastrointestinal tract and the development of novel mineral-based therapeutics. Dr Faria contributed to invention of the patented technology behind IHAT which Nemysis Ltd acquired the licence from the MRC in late 2017.

Dr Dora Pereira

Dr Dora Pereira

Medical advisor at Vifor, UK

Dr Pereria is the Medical Advisor at Vifor in the UK and was a Research Group Leader at the Department of Pathology, University of Cambridge. Her research focuses on understanding the risk-benefit balance of oral iron in iron deficiency, the gut microbiome and enteric infections. She was a Principal Investigator with the MRC Unit The Gambia on a clinical trial investigating the safety and efficacy of oral iron supplements in young children. Dr Pereira contributed to invention of the patented technology behind IHAT.

Dr Geoffrey Block

Dr Geoffrey Block

Director of Research at Denver Nephrology Research

Dr Geoffrey Block is the Director of Research at Denver Nephrology Research, a department he founded in 1998 to provide translational research for patients with chronic kidney disease. His work focuses on mineral metabolism, cardiovascular disease (including anaemia management) and reno-protective therapy (anti-inflammatory). He has been the principal investigator on over 95 clinical trials spanning all phases of clinical research; has served on several international guideline committee workgroups, a steering committee member of several international clinical outcome clinical trials, and has been elected to the Executive Committee of KDIGO (Kidney Disease: Improving Global Outcome).

Dr Carmen Gianfrani

Dr Carmen Gianfrani

Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research

Dr Carmen Gianfrani is an immunologist, Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research (IBBC - CNR). Her scientific interest is mainly focused on the pathogenesis of gluten related disorders and immunotherapies to restore oral tolerance to gluten proteins in Celiac Disease patients. She has also contributed to develop biochemical strategies detoxifying wheat gluten, that are currently in clinical trials. Dr Gianfrani is section editor of Pediatric Research and coordinator of Science Outreach Program at IBP CNR.